Reverse inflammaging: Long-term effects of HCV cure on biological age

Oltmanns, Carlos; Liu, Zhaoli; Mischke, Jasmin; Tauwaldt, Jan; Mekonnen, Yonatan Ayalew; Urbanek-Quaing, Melanie; Debarry, Jennifer; Maasoumy, Benjamin; Wedemeyer, Heiner; Kraft, Anke; Xu, Cheng‐Jian; Cornberg, Markus

doi:10.1016/j.jhep.2022.08.042

Cited by 18 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that high viral load may influence host gene expression and immune responses. In line with other studies [ 5 – 7 ], the authors raised the interesting hypothesis that high HCV replication may induce epigenetic modifications associated with stable expression of ISG negative regulators which could persist after cure. However, the factors regulating ISG responses are unknown and would require more investigation.…”

supporting

confidence: 67%

Unraveling the role of the liver myeloid compartment during hepatitis C virus cure

Crouchet

Baumert

2024

Journal of Hepatology

View full text Add to dashboard Cite

supporting

confidence: 67%

Unraveling the role of the liver myeloid compartment during hepatitis C virus cure

Crouchet

Baumert

2024

Journal of Hepatology

View full text Add to dashboard Cite

“…Although sarcopenia was initially recognised as an age‐related loss of skeletal muscle, this clinical condition has been expanded to include a broad range of chronic diseases, including chronic liver diseases 6–9 . Recently, DAA‐induced SVR was associated with reverse inflammaging in CHC patients 17 . This process was first coined by Franceschi et al.…”

Section: Discussionmentioning

confidence: 99%

“…16 More recently, a longitudinal investigation including patients with CHC who achieved sustained virologic response (SVR) after DAA therapy demonstrated that HCV eradication can result in reverse inflammaging. 17 In older individuals, pieces of evidence pointed to inflammaging as an imbalanced secretion of proinflammatory cytokines that might be either naturally emerged with ageing or can be aggravated by external factors. 18,19 These inflammatory mediators can directly or indirectly impact skeletal muscle loss, accelerating muscle protein degradation and intensifying sarcopenia.…”

Section: Introductionmentioning

confidence: 99%

Skeletal muscle mass increases after viral eradication with direct‐acting antivirals in patients with chronic hepatitis C: A longitudinal study

Coelho,

de Vries,

Pires

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundResults of studies evaluating the effect of viral eradication following direct‐acting antiviral (DDA) therapy on skeletal muscle mass of patients with chronic hepatitis C (CHC) are scarce.AimTo assess the components of sarcopenia (low muscle mass, low muscle strength and low physical performance) in a cohort of CHC individuals before and after DAA therapy.MethodsWe performed a longitudinal study of patients with CHC who underwent body composition assessment before (T0), and at 12 (T1) and 48 (T2) weeks after DDA therapy. Bioelectrical Impedance Analysis was used to assess skeletal mass muscle (SM) and phase angle (PhA). SM index (SMI) was calculated by dividing the SM by squared height. Muscle function was evaluated by hand grip strength (HGS) and timed up‐and‐go (TUG) test. Mixed‐effects linear regression models were fitted to SMI, HGS and physical performance and were used to test the effect of HCV eradication by DAA.Results62 outpatients (mean age, 58.6 ± 10.8 years; 58% with compensated cirrhosis) were included. Significant decreases in liver fibrosis markers and an increase of 0.20 and 0.22 kg/m2 in the SMI were observed at T1 and T2. Following DAA therapy, an increase of one unit of PhA was associated with a reduction of 0.38 min in TUG.ConclusionHCV eradication with DAA therapy was associated with a dynamic reduction of non‐invasive markers of liver fibrosis and increased muscle mass in 62 patients with CHC who had an undetectable HCV load at 12 weeks after completion of antiviral treatment.

show abstract

“…Persistent virus-induced epigenetic modifications have been observed in miRNA levels, histone modifications, and gene methylation. [6][7][8][9] These genomic scars may be instrumental to understand disease mechanisms, serve as urgently needed biomarkers for residual HCC risk, and represent potential therapeutic targets in HCV-cured patients. 10 In this context, a new study published in this issue of Cellular and Molecular Gastroenterology and Hepatology by Nishikawa et al, 11 sheds new light on the epigenetic memory of chronic infection in HCV-cured patients with functional impact on gene expression pattern.…”

Section: Editorialmentioning

confidence: 99%